Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309331 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Sara Rodríguez-Enríquez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Control Metabólico, Carrera de Médico Cirujano de la Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México…. Hauptthemen laut MEDLINE: Auranofin, Drug Repositioning, Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONAHCyT-México, PAPIIT, DGAPA-UNAM, México, National Institute of Chemical Physics and Biophysics (NICPB), Tallinn, Estonia Institutional Development Fund.
Abstract (Originalsprache)
Objective
Cytotoxicity of the antirheumatic drug auranofin (Aur) and the non-steroidal anti-inflammatory drug meclofenamic acid (MA) on several cancer cell lines and isolated mitochondria was examined to assess whether these drugs behave as oxidative phosphorylation inhibitors.
Methods
The effect of Aur or MA for 24 h was assayed on metastatic cancer and non-cancer cell proliferation, energy metabolism, mitophagy and metastasis; as well as on oxygen consumption rates of cancer and non-cancer mitochondria.
Results
Aur doses in the low micromolar range were required to decrease proliferation of metastatic HeLa and MDA-MB-231 cells, whereas one or two orders of magnitude higher levels were required to affect proliferation of non-cancer cells. MA doses required to affect cancer cell growth were one order of magnitude higher than those of Aur. At the same doses, Aur impaired oxidative phosphorylation in isolated mitochondria and intact cells through mitophagy induction, as well as glycolysis. Consequently, cell migration and invasiveness were severely affected. The combination of Aur with very low cisplatin concentrations promoted that the effects on cellular functions were potentiated.
Conclusion
Aur surges as a highly promising anticancer drug, suggesting that efforts to establish this drug in the clinical treatment protocols are warranted and worthy to undertake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratorio de Control Metabólico, Carrera de Médico Cirujano de la Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
- Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
- Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
- Laboratorio de Control Metabólico, Carrera de Biología de la Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
- Laboratory of Chemical Biology, National Institute of Chemical Physics and Biophysics, Tallinn, Estonia.
ORCID-Profile: Sara Rodríguez-Enríquez, Diana Xochiquetzal Robledo-Cadena, Joaquín Alberto Padilla-Flores
Förderung
- CONAHCyT-México
- PAPIIT, DGAPA-UNAM, México
- National Institute of Chemical Physics and Biophysics (NICPB), Tallinn, Estonia Institutional Development Fund
Zitieren
APA
Rodríguez-Enríquez, S., Robledo-Cadena, D. X., Pacheco-Velázquez, S. C., Vargas-Navarro, J. L., Padilla-Flores, J. A., Kaambre, T., & Moreno-Sánchez, R. (2024). Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs. PLOS ONE. https://doi.org/10.1371/journal.pone.0309331
Vancouver
Rodríguez-Enríquez S, Robledo-Cadena DX, Pacheco-Velázquez SC, Vargas-Navarro JL, Padilla-Flores JA, Kaambre T, et al. Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs. PLOS ONE. 2024. doi:10.1371/journal.pone.0309331
BibTeX
@article{RodrguezEnrquez2024,
author = {Rodríguez-Enríquez, Sara and Robledo-Cadena, Diana Xochiquetzal and Pacheco-Velázquez, Silvia Cecilia and Vargas-Navarro, Jorge Luis and Padilla-Flores, Joaquín Alberto and Kaambre, Tuuli and Moreno-Sánchez, Rafael},
title = {Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309331}
}
EUVIMED